Catecholamine Agonists

Epinephrine is a full agonist at alpha-1, alpha-2, beta-1, beta-2, and beta-3 receptors. The cardiovascular effect at any given dose reflects which receptor populations predominate in the target tissue at that plasma concentration. At low infusion rates, beta-2-mediated vasodilation in skeletal muscle vasculature is significant enough to reduce total peripheral resistance, so mean arterial pressure may remain stable or fall slightly despite increased cardiac output. At higher doses or during bolus injection, alpha-1 activation becomes dominant in most vascular beds, producing net vasoconstriction, rising blood pressure, and widening pulse pressure.

Beta-1 stimulation at all doses increases heart rate, contractility, and atrioventricular node conduction velocity. Epinephrine also lowers the threshold for ventricular arrhythmias — an effect that is amplified by hypoxia, acidosis, and certain anesthetics, and that limits its use to genuine emergencies in patients with coronary artery disease.

Epinephrine is the only first-line treatment for anaphylaxis, with no absolute contraindications in that setting. Its value lies precisely in the breadth of its receptor activity — it simultaneously addresses all three pathophysiological components of anaphylaxis. Alpha-1 activation reverses the vasodilation and vascular permeability that produce hypotension and angioedema. Beta-1 activation supports cardiac output in the setting of distributive shock. Beta-2 activation reverses bronchoconstriction and, importantly, inhibits further release of histamine and leukotrienes from mast cells and basophils, blunting the ongoing allergic response.

The correct route is intramuscular injection into the mid-anterolateral thigh (vastus lateralis muscle) — not the deltoid, not subcutaneous. The thigh produces higher peak plasma concentrations more rapidly. The dose for adults is 0.3 to 0.5 mg of the 1:1,000 solution (1 mg per milliliter), repeated every 5 to 15 minutes if there is no response. Intravenous epinephrine in anaphylaxis is reserved for patients already in cardiac arrest or in refractory shock with continuous hemodynamic monitoring — an intravenous bolus in an awake patient can precipitate severe hypertension or ventricular arrhythmias.

During cardiopulmonary resuscitation, epinephrine 1 mg is administered intravenously every 3 to 5 minutes. The primary mechanism during cardiac arrest is alpha-1-mediated vasoconstriction, which raises aortic diastolic pressure and thereby increases coronary perfusion pressure during the compression phase — improving the likelihood of restoring spontaneous circulation. The beta-1 cardiac stimulation becomes relevant after return of spontaneous circulation rather than during the arrest itself.

Evidence from the PARAMEDIC2 trial (2018) showed that epinephrine increased return of spontaneous circulation and survival to hospital discharge but did not improve neurologically favorable survival at 30 days — a nuance that has shifted the framing of epinephrine in cardiac arrest from an unqualified benefit to a drug that improves short-term survival with uncertain neurological implications.

Epinephrine is added to local anesthetic solutions at concentrations of 1:100,000 to 1:200,000 to produce local alpha-1-mediated vasoconstriction at the injection site. This slows systemic absorption of the local anesthetic, prolonging its duration of action and reducing peak plasma concentration — which in turn reduces the risk of local anesthetic systemic toxicity. It also reduces bleeding in the surgical field.

Epinephrine is contraindicated as a local anesthetic additive in anatomical locations supplied by end arteries — the digits, the penis, the tip of the nose, and the ear lobes. In these locations, alpha-1-mediated vasoconstriction can cause complete arterial occlusion and ischemic necrosis, since there are no collateral vessels to maintain perfusion.

At low infusion rates (approximately 1 to 3 micrograms per kilogram per minute), dopamine activates D1 receptors in the renal and mesenteric vasculature, producing regional vasodilation and natriuresis. At moderate rates (approximately 3 to 10 micrograms per kilogram per minute), beta-1 receptor activation dominates, increasing cardiac contractility and heart rate and raising cardiac output. At high rates (above 10 micrograms per kilogram per minute), alpha-1 activation produces systemic vasoconstriction, and the hemodynamic profile resembles norepinephrine.

These dose ranges are approximations, not pharmacological guarantees. Individual variability in receptor density, volume status, and baseline sympathetic tone means the transitions between these phases are not sharp in clinical practice.

For decades, low-dose dopamine (1 to 3 micrograms per kilogram per minute) was used clinically to protect the kidneys from acute injury, based on the physiological rationale that D1 receptor activation produces renal vasodilation and natriuresis. Multiple randomized controlled trials have definitively disproven this rationale. The landmark Australian and New Zealand Intensive Care Society trial found no difference in peak creatinine, need for renal replacement therapy, or intensive care unit length of stay between low-dose dopamine and placebo in patients with early renal dysfunction. Low-dose dopamine does not prevent acute kidney injury in any clinical context and should not be used for that purpose.

The Sepsis Occurrence in Acutely Ill Patients II trial established norepinephrine as the preferred vasopressor over dopamine for septic shock, driven by dopamine's significantly higher arrhythmia rate (24 percent versus 12 percent) and worse outcomes in the cardiogenic shock subgroup. Dopamine retains a limited role in bradycardia with hypotension when atropine has failed and a chronotropic effect is specifically desired.

Beyond arrhythmias, dopamine causes nausea and vomiting through D2 receptor activation in the chemoreceptor trigger zone, causes tissue necrosis on extravasation (managed with phentolamine, same as norepinephrine), and suppresses pituitary hormone secretion during prolonged infusion. Central venous access is required for administration.

Monoamine oxidase inhibitors irreversibly inhibit the enzymes responsible for catecholamine degradation at the nerve terminal and in peripheral tissues. When catecholamines — or drugs that cause catecholamine release (indirect sympathomimetics such as ephedrine, amphetamines, or dietary tyramine) — are given to a patient taking a monoamine oxidase inhibitor, the inability to catabolize the excess catecholamine leads to prolonged, severely exaggerated sympathomimetic effects. The result can be a hypertensive crisis with severe headache, hypertensive encephalopathy, intracerebral hemorrhage, pulmonary edema, and death.

Because monoamine oxidase inhibitor-mediated enzyme inhibition is irreversible, new enzyme must be synthesized before normal catecholamine metabolism is restored. This takes approximately two weeks. Catecholamines and indirect sympathomimetics must be avoided or used with extreme caution for the full two-week washout period after monoamine oxidase inhibitor discontinuation. When a vasopressor is unavoidable in a monoamine oxidase inhibitor-exposed patient, phenylephrine — a pure direct alpha-1 agonist with no indirect effects — is the safest choice, used at the lowest effective dose with continuous monitoring.

Tricyclic antidepressants block the norepinephrine transporter, preventing reuptake of catecholamines from the synapse back into the presynaptic terminal. This reuptake blockade prolongs and amplifies the effect of any direct-acting catecholamine (epinephrine, norepinephrine, phenylephrine) because the drug remains in the synapse longer at higher effective concentration. Standard doses can produce exaggerated and prolonged cardiovascular responses; dose reduction and careful monitoring are required when direct-acting catecholamines must be used in tricyclic antidepressant-treated patients.

The reciprocal effect applies to indirect-acting sympathomimetics (ephedrine, amphetamines): tricyclic antidepressant-mediated transporter blockade reduces catecholamine uptake into nerve terminals, depleting the releasable pool and making indirect agents less effective.

Patients taking non-selective beta-blockers (propranolol, nadolol) present a management challenge during anaphylaxis. Beta-blockade prevents epinephrine from activating beta-2 receptors (blocking bronchodilation) while leaving its alpha-1-mediated vasoconstrictive effects unopposed. The result is paradoxical severe hypertension with persistent bronchospasm — the opposite of what is needed.

The pharmacological rescue is glucagon, 1 to 2 milligrams given intravenously. Glucagon activates its own receptor, which couples to Gs and increases cardiac cyclic adenosine monophosphate independently of beta-adrenergic receptors. This provides positive inotropy and bronchodilation through a pathway that completely bypasses the blocked beta receptors. Higher and repeated doses of epinephrine are also required, and nebulized ipratropium provides additional bronchodilation through a cholinergic-independent mechanism.

Cocaine blocks the norepinephrine transporter and dopamine transporter, potentiating catecholamine effects by the same reuptake inhibition mechanism as tricyclic antidepressants. In a cocaine-intoxicated patient already in a state of catecholamine excess (tachycardia, hypertension, hyperthermia), administering additional catecholamines risks precipitating hypertensive crisis or ventricular arrhythmias. Beta-blockers are contraindicated in cocaine-associated cardiovascular toxicity because blocking beta receptors in a state of catecholamine excess leaves alpha-1 vasoconstriction unopposed, worsening hypertension and coronary vasospasm. Benzodiazepines (to reduce central sympathetic outflow), phentolamine (non-selective alpha blocker for hypertension), and nitrates are the preferred agents.